Zhisheng Technology Completes RMB 10 Million Series A Funding to Advance Innovative Digital Solutions for Neurocognitive Disorders

It is reported that a provider of innovative diagnostic and therapeutic solutions for brain and neurological health in the digital healthcare sectorZhiSheng TechAnnounced the completion of its first round of financing, with the disclosed amount being approximately RMB 10 million. The investor was Nuoyu Capital.

Zhisheng TechnologyEstablished in Shanghai in March 2020, the company is dedicated to driving innovation in early screening, clinical diagnosis, and intervention methods within the field of brain and neurological health. Its current focus is an “eye-tracking” technology model, a novel “hardware-software integrated” digital solution developed through deep learning training based on the “brain-eye” neural feedback mechanism and combined with clinically collected data. After two years of technological accumulation, this model is expected to enter pre-clinical validation no later than the second quarter of this year, with Alzheimer’s Disease (AD) selected as the initial indication.

The pathogenesis of Alzheimer’s disease (AD) remains unclear, and effective treatments are lacking. Nevertheless, AD has become the fifth leading cause of death in China, surpassed only by stroke, ischemic heart disease, chronic obstructive pulmonary disease, and lung cancer, with an average survival time of just 5.5 years. More than 85% of patients present with moderate to severe disease at their initial clinical visit; therefore, early screening, diagnosis, and intervention are particularly crucial for patient prognosis. According to the “China Alzheimer’s Disease Report 2021,” as of 2019, the number of individuals living with dementia, including Alzheimer’s disease (AD), exceeded 13 million in China, while the population exhibiting prodromal symptoms, including mild cognitive impairment (MCI), had surpassed 50 million.

Currently, the prevailing clinical diagnostic approach for Alzheimer’s disease (AD) relies on self-assessment by subjects and evaluation by clinicians using standardized scales as a foundational reference, further integrated with brain imaging (such as resting-state MRI) and biological biomarker testing to establish a clinical diagnosis. However, in practical diagnostic settings, scale-based assessments are influenced by a range of subjective factors, including the subject’s educational background and comprehension abilities. Moreover, there is no consensus among clinicians regarding optimal cutoff thresholds and score interpretations when applying these tools across diverse populations varying in age, sex, education level, and other demographic characteristics. Consequently, there is an urgent need in the field for more objective diagnostic tools that require minimal manual intervention.

WeaveBio TechThe currently promoted "eye-tracking" technology model can assess subjects' cognitive status in a more objective manner, while significantly reducing the need for manual intervention throughout the evaluation process. This innovative model can greatly lower the threshold for diagnosing Alzheimer's disease (AD) and substantially improve diagnostic accuracy, thereby enabling more professional and cost-effective early screening for the condition. Through subsequent clinical data validation,Zhisheng TechnologyWe aim to further refine “eye-tracking” technology models to address the limitations of existing diagnostic tools, establish them as a novel auxiliary diagnostic method, and drive innovation in current diagnostic standards.

Through subsequent clinical applications and technological R&D,ZhiSheng TechThe plan is to further apply the “eye-tracking” technology model to the diagnosis of prodromal symptoms of Alzheimer’s disease (AD), including subjective cognitive decline (SCD) and mild cognitive impairment (MCI).

WeaveLife TechMr. Ye Jianfeng, the founder, stated,WeaveLife TechnologiesThe core R&D team hails from top academic institutions such as MIT, the University of Cambridge, and the Chinese Academy of Sciences, possessing profound expertise in neuroscience and cognitive science. The application scenarios for the "eye-tracking" technology model are not limited to diagnosis; interventions for the early and middle stages of Subjective Cognitive Decline (SCD), Mild Cognitive Impairment (MCI), and Alzheimer’s Disease (AD) have already entered the trial phase. It is foreseeable that this digital solution will usher in a new revolution in the field of AD intervention. Meanwhile, feasibility studies on the application of this model in other neurological disorders, including Attention Deficit Hyperactivity Disorder (ADHD), Parkinson’s Disease (PD), and Autism Spectrum Disorder (ASD), will be carried out in subsequent phases.

Mr. Yang Zhiwen, Managing Partner at Nuoyu Capital, stated that Alzheimer’s disease (AD) is far more than just a loss of cognitive function in patients; the disrupted sleep-wake cycles, characterized by reversed day-night patterns, can wreak devastating havoc on the normal work and daily lives of all family members. Regrettably, the medical community currently has no cure for Alzheimer’s disease, making early detection and early intervention the only viable approach. According to long-term clinical follow-up studies, early intervention can delay the onset of Alzheimer’s disease by 7–8 years. For most patients who would typically develop the condition around the age of 80, this delay may mean they never manifest the disease in their lifetime.WeaveLife TechnologiesTheir “eye-tracking” technology model represents a revolutionary breakthrough in the early screening of Alzheimer’s disease (AD). We are firmly optimistic about their future and believe that their technology can benefit tens of millions of individuals at risk for Alzheimer’s disease (AD).

Nuoyu Capital is a specialized investment firm focused on medical devices and digital health. Our vision is to become an incubator for outstanding healthcare enterprises, which drives us to continuously seek out entrepreneurs who can truly address medical challenges. Every member of our investment team has over ten years of practical experience in the healthcare industry, shaping our approach to investing with an operator’s mindset. We have long upheld the collaborative principles of integrity, kindness, and inclusivity in our interactions with every entrepreneur. We firmly believe that integrity simplifies the world; practicing kindness inevitably attracts kindness; and only inclusive environments can nurture greatness. Entrepreneurship is a perilous endeavor with high stakes. Leveraging our extensive industry experience, the Nuoyu team aspires to be a trusted partner for founders, navigating storms and riding the waves together through thick and thin.

Key Investment Projects: Changmugu Medical, Wevis Medical, Huihe Medical, Tingsheng Technology, Zhisheng Technology, Qianglian Zhichuang.

ZhiSheng TechEstablished in Shanghai in March 2020, the company specializes in the research, development, and application of digital healthcare solutions for brain and neurological health. Its core R&D team hails from top-tier academic institutions such as MIT, the University of Cambridge, and the Chinese Academy of Sciences, possessing extensive expertise in neuroscience and cognitive science.ZhiSheng TechnologyDedicated to applying innovative technologies, such as eye-tracking models, to address the limitations of existing diagnostic and therapeutic tools for various neurological disorders—including Alzheimer’s Disease (AD), Attention Deficit Hyperactivity Disorder (ADHD), Parkinson’s Disease (PD), and Autism Spectrum Disorder (ASD)—thereby driving a revolution in related diagnostic standards and intervention strategies through innovative approaches.